FOXM1 predicts disease progression in non-muscle invasive bladder cancer.
Sebastien RinaldettiRalph WirtzThomas Stefan WorstArndt HartmannJohannes BreyerLars DyrskjotPhilipp ErbenPublished in: Journal of cancer research and clinical oncology (2018)
FOXM1 is a highly prognostic marker for disease progression of NMIBC superior to current histological, clinical and molecular staging methods and MKI67. It is mainly expressed in the Class 2 and genomically unstable molecular bladder cancer subtypes. Its role in drug resistance development makes FOXM1 valuable biomarker for NMIBC risk stratification.
Keyphrases